Abstract
Positron emission tomography (PET) is a powerful and rapidly developing area of molecular imaging that is used to study and visualize human physiology by the detection of positron-emitting radiopharmaceuticals. Information about metabolism, receptor/enzyme function, and biochemical mechanisms in living tissue can be obtained directly from PET experiments. In particular, the interest in 18F-labeled proteins remains high for both diagnoses and therapy monitoring purposes. The development of labeling strategies for the synthesis of new 18F labeled protein is, however, not trivial. 18F-containing prosthetic groups are often required for protein labeling to obtain high yield under mild labeling conditions and keep the bioactive character of the proteins. This review highlights key aspects of protein 18F-labeling method and discussed representative examples including 18F-labeled human serum albumin, 18F-labeled Annexin V, 18F-labeled HER2 affibody, and 18F-labeled low density lipoprotein.
Keywords: 18F, Amine reactive prosthetic groups, Carboxylic acid reactive prosthetic groups, Thiol-reactive prosthetic groups, 18F-Labeled proteins, Positron emission tomography (PET)
Current Pharmaceutical Biotechnology
Title: 18F-Labeled Proteins
Volume: 11 Issue: 6
Author(s): Zhanhong Wu and Fouad Kandeel
Affiliation:
Keywords: 18F, Amine reactive prosthetic groups, Carboxylic acid reactive prosthetic groups, Thiol-reactive prosthetic groups, 18F-Labeled proteins, Positron emission tomography (PET)
Abstract: Positron emission tomography (PET) is a powerful and rapidly developing area of molecular imaging that is used to study and visualize human physiology by the detection of positron-emitting radiopharmaceuticals. Information about metabolism, receptor/enzyme function, and biochemical mechanisms in living tissue can be obtained directly from PET experiments. In particular, the interest in 18F-labeled proteins remains high for both diagnoses and therapy monitoring purposes. The development of labeling strategies for the synthesis of new 18F labeled protein is, however, not trivial. 18F-containing prosthetic groups are often required for protein labeling to obtain high yield under mild labeling conditions and keep the bioactive character of the proteins. This review highlights key aspects of protein 18F-labeling method and discussed representative examples including 18F-labeled human serum albumin, 18F-labeled Annexin V, 18F-labeled HER2 affibody, and 18F-labeled low density lipoprotein.
Export Options
About this article
Cite this article as:
Wu Zhanhong and Kandeel Fouad, 18F-Labeled Proteins, Current Pharmaceutical Biotechnology 2010; 11 (6) . https://dx.doi.org/10.2174/138920110792246564
DOI https://dx.doi.org/10.2174/138920110792246564 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemosensitization of Prostate Carcinoma Cells with a Receptor-directed Smac Conjugate
Medicinal Chemistry Prevention of Non-communicable Diseases by Balanced Nutrition: Population- specific Effective Public Health Approaches in Developing Countries
Current Diabetes Reviews Nanosponge Carriers- An Archetype Swing in Cancer Therapy: A Comprehensive Review
Current Drug Targets How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry The Value of Biomarkers in Optimizing the Use of Immuno-oncologic Therapy
Current Drug Targets Role of Genetic Interactions in Lung Diseases Detection Using Computational Approaches: A Review
Current Chinese Computer Science Chemical and Genetic Engineering Strategies to Improve the Potency of Pharmaceutical Proteins and Enzymes
Current Medicinal Chemistry Molecular Mechanisms of Biological Activity of Oleanolic Acid - A Source of Inspiration for A New Drugs Design
Mini-Reviews in Organic Chemistry Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Ultrasound Assisted-synthesis and Biological Evaluation of Piperazinylprop- 1-en-2-yloxy-2H-chromen-2-ones as Cytotoxic Agents
Letters in Drug Design & Discovery Development of A Novel System Based on Green Magnetic / Graphene Oxide / Chitosan /Allium Sativum / Quercus / Nanocomposite for Targeted Release of Doxorubicin Anti-Cancer Drug
Anti-Cancer Agents in Medicinal Chemistry Editorial from Editor-in-Chief. Postoperative Pulmonary Complications and the Importance of the Preoperative Evaluation
Current Respiratory Medicine Reviews Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy SCYL1-BP1 Affects Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells via Cyclin F and RRM2
Anti-Cancer Agents in Medicinal Chemistry Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation
Current Genomics Drug-Lipid Membrane Interaction Mechanisms Revealed Through Molecular Simulations
Current Physical Chemistry Antisense Technologies Targeting Fatty Acid Synthetic Enzymes
Recent Patents on Anti-Cancer Drug Discovery Editorial [ Hot Topic:Emerging Anticancer Effects of Antiresorptive Therapies (Guest Editor: Vera Hirsh)]
Anti-Cancer Agents in Medicinal Chemistry Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery STAT Inhibition in the Treatment of Cancer: Transcription Factors as Targets for Molecular Therapy
Current Cancer Therapy Reviews